Everis Medical acquires E Benson Hood Laboratories

Everis Medical has acquired Hood Laboratories, a transaction that underscores its strategy to consolidate and expand in the specialized medical technology sector. The acquisition, terms of which remain undisclosed, brings Hood Laboratories' well-established expertise in ENT and airway devices into the fold of Everis' evolving portfolio. This marks the fifth strategic acquisition by Everis since its inception in 2019, aimed at enhancing its offerings in Otolaryngology/Head and Neck Surgery (OHNS) and entering the airway management domain.

Founded in 1962 and based in Pembroke, Massachusetts, Hood Laboratories has a longstanding reputation as a leading manufacturer of devices across ENT, rhinology, laryngology, thoracic surgery, and interventional pulmonology. The acquisition allows Everis to integrate Hood's specialized product lines — including T-Tubes, critical for treating tracheal stenosis — thereby offering comprehensive solutions spanning diagnostic, surgical, and post-operative care. According to Kevin McLeod, CEO of Everis Medical, the move is intended to streamline product availability, ultimately aiming to improve patient outcomes by combining complementary technologies.

Expanding its portfolio in the Otolaryngology and airway management sectors aligns with Everis’ broader strategy of sector-targeted growth, largely driven by previous acquisitions such as the Cook Medical OHNS line and the Shaw Scalpel. The backing of Shore Capital Partners further facilitates Everis' capacity to enhance its product offerings and support customer service. Integration of Hood Laboratories allows Everis to continue its trajectory of growth and innovation in emerging medical technology markets.

For competitors, Everis’ acquisition of Hood Laboratories highlights the ongoing consolidation within the medical device industry, particularly for niche product lines. As Everis continues to acquire specialized technologies, other players in this space may face increased pressure to fortify their positions through either internal R&D or similar acquisitions, potentially setting the stage for an uptick in deal activity.

Looking ahead, Everis will focus on seamless integration with Hood Laboratories to maintain uninterrupted product service and support for existing customers. The acquisition further suggests Everis will continue scouting for opportunistic acquisitions to bolster its portfolio and expand its footprint in related medical technology areas. Any significant future moves could alter the competitive landscape and shape ensuing industry dynamics.